XBiotech
XBIT
53 hedge funds and large institutions have $10.1M invested in XBiotech in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 18 closing their positions.
3.48% less ownership
Funds ownership: 14.69% → 11.2% (-3.5%)
4% less funds holding
Funds holding: 55 → 53 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
30% less capital invested
Capital invested by funds: $14.5M → $10.1M (-$4.36M)
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.36M |
| 2 |
RC
RBF Capital
San Francisco,
California
|
+$581K |
| 3 |
Goldman Sachs
New York
|
+$189K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$139K |
| 5 |
Squarepoint
New York
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.65M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$699K |
| 3 |
State Street
Boston,
Massachusetts
|
-$469K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$341K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$338K |
XBIT Hedge Fund Activity: Q2 2025 in Review
53 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2025, worth a combined $10.1M — down 30% from $14.5M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of XBIT and 16 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, adding an estimated $1.36M. The largest seller was BlackRock, cutting an estimated $2.65M.
- 53 institutional investors held XBiotech (XBIT) as of Q2 2025, down from 55 in Q1 2025.
- Funds reported $10.1M of XBiotech stock for Q2 2025, down 30% quarter-over-quarter.
- 16 funds opened new XBiotech positions in Q2 2025 and 18 closed out, a net change of -2 holders.
- The largest XBiotech buyer in Q2 2025 was Millennium Management, an estimated $1.36M added.
- The largest XBiotech seller in Q2 2025 was BlackRock, an estimated $2.65M sold.
Based on aggregated 13F filings for Q2 2025.